China Pharma Holdings, Inc. (CPHI) News

China Pharma Holdings, Inc. (CPHI): $0.25

0.00 (-0.04%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CPHI to Watchlist
Sign Up

Industry: China


Ranked

of 65

in industry

Filter CPHI News Items

CPHI News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest CPHI News From Around the Web

Below are the latest news stories about China Pharma Holdings Inc that investors may wish to consider to help them evaluate CPHI as an investment opportunity.

China Pharma Holdings, Inc. Reports Third Quarter 2021 Financial Results

China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced the financial results for the quarter ended September 30, 2021.

Yahoo | November 12, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Good morning, investor!

William White on InvestorPlace | October 28, 2021

China Pharma Holdings, Inc. Reports Second Quarter 2021 Financial Results

China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced the financial results for the quarter ended June 30, 2021.

Yahoo | August 13, 2021

China Pharma's Candesartan Hypertension Product Passes Bioequivalence Tests and the Company Plans to Apply for NMPA Approval

China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that its Candesartan hypertension product passed key bioequivalence tests. The Company plans to use the results of the key benchmark tests of consistency evaluation to apply for the National Medical Products Administration's (NMPA) approval. The NMPA is the Chinese agency for regulating drugs and medical devices (formerly the China Food and Drug Administr

Yahoo | August 5, 2021

China Pharma to Launch Highly Purified NMN+PQQ Product

China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced plans to launch a highly purified NMN+PQQ product following the recent successful completion of a pilot scale test. β-Nicotinamide mononucleotide (NMN) is a derivative of the B-vitamin niacin, which is believed to significantly improve health and wellness.

Yahoo | June 9, 2021

China Pharma Holdings, Inc. Reports 33% YoY Increase in First Quarter 2021 Revenue

China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced financial results for the quarter ended March 31, 2021.

Yahoo | May 14, 2021

China Pharma Expects Considerable Increase in Growth Opportunities Related to Hainan Free Trade Port

China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, commented on the policy statements in "Several Special Measures to Support the Construction of Hainan Free Trade Port to Relax Market Access" released by the National Development and Reform Commission and the Ministry of Commerce in April. This statement follows the release of the Overall Plan for the Construction of Hainan Free Trade Port in June 2020 and the establishment of the Hainan Boao Lecheng International Medical Tourism Pilot District in 2013, which were both approved by the State Council.

Yahoo | April 19, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5578 seconds.